Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
12 September 2023 - 10:50PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
the initiation of an exploratory feasibility study evaluating a
selected delivery mechanism for its intranasal therapeutic drug
SPC-15. The Company’s collaboration partner for the study is a
developer and manufacturer of innovative drug delivery systems and
technology.
Eric Weisblum, Chief Executive Officer of Silo Pharma, stated,
“We believe our research partner’s patented proprietary
nasal-to-brain technology could be well suited for the delivery of
SPC-15, and we expect to receive the results of these in vitro lab
tests by the end of September. If the results are positive, we will
work to prepare an Investigational New Drug (IND) application for
submission to the FDA in the first quarter of 2024.”
SPC-15, a Serotonin 4 receptor agonist with prophylactic
efficacy against stress, utilizes biomarkers for the treatment of
stress-induced affective disorders, anxiety, and PTSD. Its
core technology is patent-protected.
About Silo Pharma Silo Pharma. Inc. is a
development-stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research for people
suffering from indications such as PTSD, Alzheimer’s disease, and
other rare neurological disorders. Silo’s mission is to identify
assets to license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information visit www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2024 to May 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From May 2023 to May 2024